GlassScriptPhysician profile
Christopher Todd Kroodsma
NPI 1336230051
$1,914.41
in general payments reported to CMS, 2019-2025
14 companies · $298 in 2025
The $298 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $121 · 2021: $170 · 2022: $236 · 2023: $527 · 2024: $216 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $891.36 |
| Education | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $322.62 | 2019-2023 | |
| Abbvie INC. | $289.14 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $281.42 | 2019-2025 | |
| Amgen INC. | $256.90 | 2021-2025 | Otezla |
| Janssen Biotech, INC. | $186.86 | 2019-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $139.57 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $113.32 | 2019-2025 | Dupixent |
| Genzyme Corporation | $91.53 | 2019-2025 | |
| Galderma Laboratories, L.P. | $72.60 | 2019-2022 | |
| Ucb, INC. | $59.43 | 2019 | |
| Sun Pharmaceutical Industries INC. | $37.47 | 2023 | Ilumya |
| Arcutis Biotherapeutics, INC. | $35.06 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $14.37 | 2023 | Vtama |
| Prugen, INC. Pharmaceuticals | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kroodsma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.